川芎嗪与肝复肽联用对慢性乙型肝炎患者血清肝纤维化指标的影响  

Effect of ligustrazine combined with HSS on hepatic fibrosis indexes in patients with chronic hepatitis

作　　者：王淑萍 王晓红 邱绍勤 钱宜丹 陈长寅 向启云 

机构地区：[1]宜昌市第三人民医院肝病科,湖北宜昌443000

出　　处：《中西医结合肝病杂志》2006年第2期73-74,77,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：宜昌市科委资助项目(No.A99319)

摘　　要：目的:观察川芎嗪与肝复肽(肝细胞生长与刺激因子,HSS)联用对慢性乙型肝炎(CHB)患者血清肝纤维化指标的影响。方法:169例血清肝纤维化指标异常的CHB患者,随机分为治疗组89例,对照组80例。治疗组采用川芎嗪与肝复肽;对照组采用丹参注射液。30天为1个疗程,两组患者均用药3个疗程。于治疗前后检测血清肝纤维化指标。结果:治疗组患者治疗后肝纤维化指标(PⅢP、LN、C-Ⅳ、HA)显著低于治疗前及对照组治疗后(P<0·01);治疗组总有效率为87·64%,对照组则为70·00%,治疗组疗效显著优于对照组(P<0·05)。结论:川芎嗪与肝复肽两者联用具有纠正CHB患者血清肝纤维化指标异常的作用,两药联用可起到有效的抗肝纤维化作用。Object： To observe the effects of Ligustrazine and HSS on hepatic fibrosis Indexes in patients with chronic hepatitis. Methods： Qne hundred and sixty nine patients with chronic hepatitis were divided randomly into two groups; the control group （80 cases） and the therapy group （89 cases）. Before and after the treatment to the groups, the serum level of hyaluronicacid （HA）, type Ⅲ prooollagen peptide （PⅢP）, type IV collagen （C-Ⅳ）, type laninin （LN） were detected with ELISA. Resdts： The slrum leuel of HA, PⅢP, C-Ⅳ, LN were not significantly different in the two groups before treatment （P〈0.05）. in the therapy group the serum level of HA, PⅢP, C-Ⅳ, LN were declined significantly after treatment （P〈0.01）, the effective rate in the treatment group and cntrol group were 87.64%, 56.00%, respectively. There was a significant difference between the two groups （P〈0.01）. Conclusion： Ligustrazine and HSS can oorrect the serum level of HA, PⅢP, C-Ⅳ, LN. So they can prevent and reverse hepatic fibrosis in patients with chronic hepatitis.

关 键 词：肝炎 乙型 慢性 肝纤维化 中西医结合疗法 川芎嗪/治疗应用 肝细胞刺激生长因子/治疗应用 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]